ArticleInternational journal of chronic obstructive pulmonary disease2026
Analysis of Current Status and Influencing Factors of Inhaler Treatment Adherence Among COPD Patients.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the current status of inhaler treatment adherence and analyze its influencing factors among patients with chronic obstructive pulmonary disease (COPD) based on the clinical treatment data of a tertiary grade A hospital. Patients and Methods: A retrospective study design was adopted. COPD patients who received inhaler treatment at The First Affiliated Hospital of Shihezi University from July to December 2023 were enrolled. Their medical visit records, prescription data within 18 months after enrollment, and medical insurance reimbursement records were collected. Medication adherence was evaluated using proportion of days' supply covered (PDC) calculated from prescription and reimbursement records, not by direct measurement of actual inhaler, and patients were divided into three groups. The relationships between adherence and patients' basic characteristics, disease-related factors, and inhaler usage were analyzed. Results: A total of 706 patients were included in the study. Overall, patient adherence was poor as assessed by PDC, mean PDC of 43.67% ± 32.44%. Among them, 18.42% of patients had high adherence and 60.48% had low adherence. Male patients and those with a smoking history had higher adherence. The inhaler treatment adherence of COPD patients increased with the aggravation of the disease (Gamma = 0.267, p = 0.024), the prolongation of disease duration (r = 0.155, p < 0.01), and the increase in the number of acute exacerbations (p < 0.01). Patients using fluticasone furoate/vilanterol/umeclidinium bromide inhalation powder had higher overall adherence than those using budesonide/formoterol fumarate inhalation powder. Conclusion: Among patients with COPD at our hospital, adherence to inhaled therapy as measured by PDC is generally low. Lower PDC was observed in newly diagnosed patients and those without a history of acute exacerbations. In clinical practice, greater emphasis should be placed on medication education and long-term management for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.